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BCL11B, A T-CELL COMMITMENT FACTOR, AND ITS ROLE IN HUMAN 
IMMUNODEFICIENCY VIRUS-1 TRANSCRIPTION 
 
ANDREW J. WOERNER 
ABSTRACT 
 Advancements of antiretroviral therapies (ART) have made significant 
strides in reducing human immunodeficiency virus (HIV) viral loads in patients to 
undetectable levels. Upon interruption of ART, viral load rebounds and AIDS 
symptoms return.  Latent reservoirs of virus are responsible for this phenomenon 
because they contain integrated provirus, which is transcriptionally silent, thus 
unaffected by ART and hidden from host immune surveillance.  A commonly 
proposed mechanism for HIV latency is the presence of host cell transcription 
factors that lead to transcriptional silencing.  CD4+ T cells and other immune 
cells, whether due to their subset phenotype, activation state, or stage in 
development, will vary in their battery of transcription factors.  Of particular 
interest is Bcl11b, a critical transcription factor involved in the commitment to a T-
cell fate during thymocyte development that has recently been shown to play a 
role in silencing HIV-1 transcription. 
 Bcl11b is required for inhibiting the development of natural killer cell-like 
traits during the early development of T cells.  The repressive role of this zinc-
finger transcription factor has recently been shown to inhibit HIV-1 transcription in 
the context of microglial cells via recruitment of chromatin remodeling factors.  
Also, Bcl11b has been shown to interact with other HIV-1 transcriptional silencing 
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factors such as NuRD and NCoR.  Preliminary mass spectrophotometry results 
have pointed to a physical interaction of Bcl11b with NELF, another proven 
repressive factor of HIV transcription.    We hypothesize that Bcl11b represses 
HIV transcription and is recruited to the HIV-1 long terminal repeat (LTR) through 
a paused RNA polymerase II complex, contributing to the establishment and 
maintenance of latency.  Our studies confirm Bcl11b’s repressive role in T cells, 
and investigate the mechanism with NELF. 
 Transfection of HEK293T cells with HIV-LUC shows nearly 50% reduction 
in HIV transcription in the presence of Bcl11b, and analysis of viral protein output 
by p24 ELISA confirms this result.  Furthermore, when co-transfected with NELF-
B, the two transcription factors lead to nearly 90% reduction in HIV transcription.  
Results suggest that these factors cooperate to repress HIV transcriptional 
elongation.  Protein and chromatin immunoprecipitations (ChIP) were also 
performed to see a direct interaction between the two transcription factors and 
the HIV LTR.  Physical interaction of the two factors was not witnessed, while 
ChIP analysis shows enrichment of RNA polymerase II at the transcriptional start 
site suggesting Bcl11b increasing RNA polymerase II pausing.  We conclude that 
Bcl11b plays a repressive role in HIV transcription through promoter-proximal 
pausing with a synergistic effect with NELF, but a yet to be identified factor is 
responsible for the coordination of the two factors. 
 As an important T-cell commitment factor, Bcl11b may play an important 
role in establishing and maintaining cellular latency through transcriptional 
	  	   vii 
repression via a complex with NELF.  Confirming Bcl11b’s role as a repressive 
transcription factor and providing further support for a synergistic role with NELF, 
could highlight a new target for therapeutic strategies against the elusive latent 
reservoir. 
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INTRODUCTION 
 
There are over 34 million individuals worldwide currently infected with HIV, 
the virus that leads to acquired immunodeficiency syndrome (AIDS), and HIV is 
responsible for over 25 million deaths (“Global Statistics,” n.d.).  The number of 
annual fatalities peaked in 2005 at 2.3 million, and has been in a steady decline 
ever since.  The decline is attributed to a decrease in newly infected individuals, 
and more importantly, the increased availability of antiretroviral therapy (ART) 
(“WHO | Number of deaths due to HIV/AIDS,” n.d.).  HIV infection is becoming a 
more manageable chronic condition; however, average life expectancy is still 
over 15 years less than the general population and 6,300 individuals continue to 
be infected each day (“amfAR  : Statistics: Worldwide  : The Foundation for AIDS 
Research  : HIV / AIDS Research,” n.d.; Samji et al., 2013).  Given these 
continued drastic statistics, there is no doubt to the global impact of this disease 
from a public health and research standpoint. 
 The global AIDS epidemic came onto the scene in 1981 via the 
presentation of immunosuppressed individuals with depletion of CD4+ T 
lymphocytes suffering from a variety of opportunistic infections and diseases, 
such as Kaposi’s sarcoma and Pneumocystis pneumonia.  Two years later, 
researchers found the cause of AIDS to be HIV, and in 1987 zidovudine (or 
azidothymidine (AZT)) was introduced as the first ART (Adler, Edwards, & Miller, 
2012).  HIV belongs to the Retroviridae family of viruses, characterized by the 
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reverse transcription of a ribonucleic acid (RNA) viral genome into proviral 
deoxyribonucleic acid (DNA).  The process of reverse transcription is dependent 
on the virally encoded enzyme, reverse transcriptase (“Human Immunodeficiency 
Virus (HIV),” 2007).  The activity of this enzyme serves as the active target of the 
previously mentioned AZT.  Further development of ART, with greater efficacy 
and a lower pill-burden has significantly reduced AIDS-related morbidities and 
mortalities; however, silent reservoirs of the virus exist in infected individuals that 
remain insensitive  to ART provide a barrier to complete eradication (Lint, 
Bouchat, & Marcello, 2013). 
 
Characteristics and Life Cycle of HIV 
HIV is an 80-120 nm enveloped icosahedral sphere (a solid with 20 plane 
faces) containing a cone-shaped protein core, the surrounding capsid, and a two-
layered envelope (“Human Immunodeficiency Virus (HIV),” 2007) (see Figure 1).  
The viral genetic material, ribonucleic acid (RNA), necessary viral enzymes 
(reverse transcriptase, integrase, and protease), and other viral proteins are 
included within the capsid.  The virus’ envelope is a host-derived phospholipid 
bilayer that is acquired when it egressed from the previously infected cell.  Within 
the envelope are important viral glycoproteins necessary to propagate infection 
(“HIV/AIDS Fact Sheets,” n.d.).   
HIV entry is the first phase of the replication cycle, step 1 (see Figure 2).  
This process starts with the adhesion of the virus to a host cell, and concludes 
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with fusion of viral and host membranes primed for delivery of the viral capsid.  
Initial interaction with the cell is mediated through the viral envelope (Env) 
protein, or host cell proteins that were incorporated into the virion’s membrane 
from a previous round of replication.  Interactions may be nonspecific, such as 
Env interacting with negatively charged cell-surface heparin sulfate 
proteoglycans (Saphire, Bobardt, Zhang, David, & Gallay, 2001), or specific 
through attachment to pattern recognition receptors (Geijtenbeek et al., 2000).  
Initial interactions of the virus to host cells are neither essential nor necessary for 
infection, but the weak binding events can facilitate the proximity Env to CD4 
receptor and chemokine receptors, the primary receptor complex for HIV entry, 
increasing the overall efficiency of transmission.  Env is a trimer of gp120 and 
gp41 heterodimers. The gp120 subunit, which contains the CD4 binding site, is 
composed of five conserved domains and five variable loops; these variable 
loops assist in immune evasion and coreceptor binding.  When Env binds CD4, 
there is a rearrangement of the variable regions of gp120, facilitating coreceptor 
binding (Wilen, Tilton, & Doms, 2012).  Env interacts with the coreceptors 
CXCR4 or CCR5, depending on the tropism of the virus.  Interaction with the 
coreceptor induces exposure of the gp41 fusion peptide that  then inserts into the 
host cell membrane and facilitates fusion (step 2) (Wilen et al., 2012).  Cell 
fusion allows for viral capsid entry into the cytoplasm. 
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Figure 1. HIV Structure:  Overview of the virus structure, including: the viral 
capsid with associated viral RNA, reverse transcriptase, and integrase; and the 
viral envelope containing gp41 and gp120.  Original image from: National 
Institute of Allergy and Infectious Diseases (NIAID).  
 
 
Once inside the host cell, the viral RNA genome must be reverse 
transcribed into DNA (step 3).  HIV reverse transcriptase carries out the process 
of reverse transcribing a single stranded RNA into a double stranded DNA, which 
will be translocated into the host cell nucleus.  For step 4, the viral DNA is 
inserted into the host genome via another viral enzyme of the viral capsid, 
integrase.  Once integrated into the host cell DNA, HIV can be replicated as part 
of the host genome during cell division or transcribed to generate viral RNA (step 
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5).  In step 6 an HIV protease is responsible for post-translationally modifying the 
translated viral Gag polypeptides; this is a critical step in maturation of the 
budding virion, enhancing its infectivity (Kohl et al., 1988).  The viral particle now 
buds from the cell, capturing fragments of the host cell membrane as it egresses 
from the cell (step 7). 
Most of the aforementioned steps have been potential therapeutic targets.   
For example, the first approved HIV therapy, AZT, is a nucleoside base analog of 
thymine that, when incorporated during reverse transcription, will cause 
premature chain termination (Bozzi, D’Andrea, & Brisdelli, 2008). Other drugs 
include, non-nucleoside reverse transcriptase inhibitors, entry inhibitors, fusion 
inhibitors, integrase inhibitors, and protease inhibitors.  Having multiple targets in 
the HIV life cycle has opened the door to combined antiretroviral therapy (cART).  
cART is the use of two or more antiretroviral therapies from more than one class 
of target sites.  This strategy provides a more efficient method of decreasing 
patient viral load and preserving immune function (Wood, 1996).  The use of 
more than one approved drug also increases the difficulty for the virus to develop 
drug resistance (“What Is Antiretroviral Therapy (ART)? | aidsinfonet.org | The 
AIDS InfoNet,” n.d.) 
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Figure 2: HIV Life Cycle.  Depicted above is the life cycle of the HIV through a 
host cell.  The progression of the life cycle is as follows: attachment to host cell, 
fusion and entry of virus particles, reverse transcription, provirus integration, viral 
transcription/translation, post-translational modification, and budding of new 
virion particle.  Original image from: NIAID. 
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Viral Latency 
A significant hurdle facing a cure to HIV infection is the latent reservoirs of 
virus that are not targeted by ART.  Viral latency is defined by the establishment 
of a state of reversible nonproductive infection of cells (Siliciano & Greene, 
2011).  Several weeks following the onset of ART, patients enter an 
asymptomatic period (depicted as the 3rd phase in Figure 3), and clinicians 
originally termed this phase as a period of latency.  However, the advent of 
sensitive reverse transcription-polymerase chain reaction (RT-PCR) viremia 
assays allowed for detection of HIV replication even during the asymptomatic 
period (Piatak et al., 1993).  Also confirming the status of a stable reservoir of 
latent virus is the depiction of the viral rebound of patients (Figure 3) after the 
cessation of ART. 
 Activated CD4+ T-cells are the main target of HIV infection and the 
cytopathic effects of the virus and host immune responses leads to significant 
death of these cells (1st phase of Figure 3).  An interesting phenomenon to the 
establishment of latent reservoirs is the finding that HIV does not effectively infect 
resting CD4+ T-cells (Zack et al., 1990; Zhou, Zhang, Siliciano, & Siliciano, 
2005).  Instead, the virus exploits the foundational mechanism to the 
establishment of immunological memory.  When activated CD4+ T cells are 
infected, a small number of these cells may survive long enough to revert back to 
a resting state, which will then provide a reservoir for stably integrated and 
transcriptionally silent virus. 
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There are two types of cellular viral latency: pre-integration and post-
integration latency.  Pre-integrated latency resulting from unintegrated reverse 
transcripts does not persist more than one day in CD4+ T cells, so it does not 
account for the long-term latent reservoir and is less clinically relevant (Durand, 
Blankson, & Siliciano, 2012).  Post-integration latency displays a multifactorial 
basis and is the foundation of our current research.  In most latently infected 
cells, HIV replication is blocked at the transcriptional level, and mechanisms 
include: the chromatin structure of the HIV promoter; a lack of nuclear 
transcription factors; the presence of transcriptional repressors, such as Bcl11b 
and NELF-B (Lint et al., 2013; Schiralli Lester & Henderson, 2012).  Elucidating 
these mechanisms of transcriptional repression will bring insight into possible 
methods of activating and targeting these reservoirs by subsequent ART in a 
“binge and purge” manner. 	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Figure 3: Plasma virus levels in cART treated HIV+ individuals.  At the onset 
of cART, individuals see a decline in plasma viral load in an initial rapid phase 
and a second slower phase.  During the third phase, the plasma viral load is too 
low for clinical detection.  Cessation of cART results in a viral rebound to the 
original plasma virus levels.  Original image from: Lint et al., 2013. Retrovirology. 
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HIV Transcription in the Context of Latency 
Latent proviruses from patients undergoing ART tend to be found within 
host genes that are actively transcribed (Han et al., 2004).  Actively transcribed 
genes are found in “relaxed” chromosomal regions, termed euchromatin, and the 
non-transcribed genes found in a much more compact chromosomal structure 
referred to as heterochromatin.  This fact supports that latent virus is integrated 
into heterochromatic regions; however, in patients undergoing ART HIV 
preferentially integrates into the actively transcribed genes of resting CD4+ T 
cells (Han et al., 2004).  This leads to the idea that maintenance of latent 
reservoirs is dependent on a multifactorial mechanism, including: transcription 
initiation, RNA polymerase II recruitment, transcriptional elongation, and 
chromatin structural organization.   
A nucleosome is composed of two tetramers of histone proteins with a 147 
base pair (bp) region wrapped around it.  They are subject to an array of 
modifications that alter the accessibility of the super-helically wrapped DNA.  Of 
particular importance is post-translationalmodifications to histone tails, including 
acetylation, methylation, ubiquitylation, phosphorylation, sumoylation, and poly 
ADP-ribosylation (Goldberg, Allis, & Bernstein, 2007).  The most significant 
regulatory element of HIV is the 5’ long terminal repeat (LTR), which is bound to 
two positioned nucleosomes referred to as nuc-0 and nuc-1 (Verdin, Paras, & 
Van Lint, 1993).  These nucleosomes overlap binding sites of transcription 
factors that promote gene expression.  The status of histone acetylation of nuc-1 
	  	  	   11 
seems to play a particularly important role in regulating HIV transcription, and the 
recruitment of histone deacetylase 1 (HDAC-1) maintains a repressed 
transcriptional state.  HDAC inhibitors are currently being tested in clinical trials 
for their ability to reactivate the latent reservoirs (Archin et al., 2012) 
Transcriptional interference is another possible explanation to the latent 
reservoirs.  Interference is based on the polarity and location of the provirus 
promoter relative to host genes.  For instance, if the HIV promoter with the same 
polarity is downstream from a host gene, the RNA polymerase II (Pol II) can 
“readthrough” the HIV promoter causing displacement of key transcription factors 
located at the promoter (Lenasi, Contreras, & Peterlin, 2008).  On the other hand, 
when the provirus and host gene are of opposite polarity, RNA Pol II collisions 
can occur that lead to premature terminations (Han et al., 2008).  However, this 
method of interference can be readily overcome by activation of the HIV LTR, by 
converting it into a strong transcriptional unit (De Marco et al., 2008). 
The 5’-LTR is further divided into four functional regions or motif’s: the Tat 
(trans-activator of transcription) activating region (TAR), the promoter, the 
enhancer, and the negative/modulatory regulatory element (Schiralli Lester & 
Henderson, 2012).  The latter three elements are responsible for recruiting a 
wide range of host cell transcription factors with multiple functions that activate 
and repress HIV transcription.  A small group of these transcription factors is 
highlighted in Figure 3.  Host factors, such as Sp1, AP-1, and NF-κB are 
necessary for HIV transcription, and their availability regulates transcription.  For 
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instance, NF-κB is sequesterd in the cytoplasm of resting cells, where it exists as 
an inactive p50/p65 heterodimer bound to IkBa.  Cell activation leads to the 
heterodimer release from IkBa, and NF-κB translocation to the nucleus and 
activation of transcription (Nabel & Baltimore, 1987).  When NF-κB is unavailable 
in the nucleus, p50-p50 homodimers are bound to NF-κB’s binding site on the 5’-
LTR, which then recruit HDAC complexes to repress transcription (Williams et al., 
2006). 
Chromatin reorganization and recruitment of factors involved in initiation of 
transcription are not solely responsible for efficient transcription.  Transcriptional 
elongation plays a significant role in limiting the transcription of the provirus.  
After association of Tat with TAR, positive transcription elongation factor b (P-
TEFb) is recruited to the RNA Pol II elongation complex.  P-TEFb, made up of 
Cdk9 and CycT1, hyperphosphorylates RNA Pol II’s carboxy-terminal domain 
allowing efficient elongation.  Several host-cell factors repress transcription of the 
provirus by causing promoter-proximal RNA Pol II pausing or premature 
termination of the transcript.  Negative elongation factors, such as 5,6-dichloro-1-
β-D-ribofuranosylbenzimidazole (DRB) sensitivity-inducing factor (DSIF) and 
negative elongation factor (NELF) are responsible for promoter-proximal pausing.  
Pre-mRNA-cleavage complex 11 factor (Pcf11) is responsible for premature 
termination (Natarajan et al., 2013).  These factors are highlighted in Figure 4. 
Previous studies performed by our lab, published in Natarajan et al., 2013, 
showed that NELF has a physical and functional interaction with the nuclear 
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corepressor (NCoR1)-G protein pathway suppressor 2 (Gps2)-HDAC3 repressor 
complex.  These findings suggest NELF repressses HIV transcription by 
coordinating promoter-proximal pausing, premature termination, and chromatin 
remodeling.  Furthermore, Dr. Chanhyo Lee, in collaboration with Dr. David 
Gilmour, using mass spectrometry found a physical interaction of several factors 
with NELF complexes, which included Bcl11b.  This leads to the current study 
which aims to define the interaction of Bcl11b with HIV transcription repressor 
complexes. 
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Figure 4: NF-κB binding site and the promoter-proximal pausing complex.  
Upstream of the transcription initiation site is the NF-κB heterodimer (p50/p65) 
binding site.  When bound, the complex induces transcription initiation.  When 
NF-κB is unavailable, the site is occupied by p50/p50.  At the initiation site and 
associated with RNA Pol II, the TAR stem-loop structure is depicted with its 
association with the viral Tat and the host-cell’s P-TEFb.  Also associated are the 
negative elongation factors: NELF, DSIF, and Pcf11. Modified image from: 
Andrew J. Henderson (unpublished) 
 
Bcl11b and its possible connection to HIV latency 
Bcl11b is part of the Bcl11 family of Kruppel-like C2H2 type zinc finger 
transcription factors, and has been shown to play a significant role in the 
maturation of T lymphocytes (Satterwhite et al., 2001).  During T cell 
development, hematopoietic progenitor cells in the thymus (thymocytes) 
differentiate from a double-negative (DN) phenotype (CD4-CD8-) to a double-
positive (DP) phenotype (CD4+CD8+), and, finally, to a single-positive (SP) 
phenotype (CD4+CD8- or CD4-CD8+) (Liu, Li, & Burke, 2010).  The DN stage is 
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further subdivided into four stages (DN1-DN4).  In the transition from DN1 to 
DN2, Bcl11b is the most upregulated transcription factor during T lymphopoiesis, 
and is an important transcription factor in terminating non-T-lineage potential in 
these progenitor cells (David-Fung et al., 2009). 
In studies performed by Wakabavashi et al. (2003), Bcl11b knockout mice 
were shown to have profound defects in T-cell receptor (TCR) expression.   The 
homozygous Bcl11b knockouts in mice are lethal with increase thymocytes 
apoptosis, diminished pre-TCR complex expression, and unsuccessful V(D)J 
rearrangements which are necessary to generate and express functional T-cell 
receptor genes.  The lack of a pre-TCR complex leads to significant apoptosis of 
thymocytes.  Heterozygous Bcl11b +/- mice are at an increased risk for 
lymphomagenesis, most likely due to blocks in T-cell differentiation and 
accumulation and outgrowth of T-cell progenitors. Taken together, these findings 
indicate that Bcl11b is an important T-cell specific factor that is necessary for 
commitment to the T-cell lineages. 
 The suppressive activity of Bcl11b remains prevalent into mature T cells.  
Expressed in both CD4+ and CD8+ T-cells, although at lower levels in CD8+, 
Bcl11b expression is lowest in activated T-cells suggesting a role in inhibiting T-
cell activation through suppressing activation-associated genes (Li et al., 2010).  
Further suppressive activity of Bcl11b appears to play a role in maintaining a T-
cell identity, as well.  When Bcl11b is conditionally deleted using tamoxifen from 
mature CD4+ T cells, there is reprogramming of the cells to a natural killer-like 
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(NK-like) cell called induced-T-to-NK-cells (ITNKs).  In development, via 
stimulation by Notch signaling, Bcl11b is responsible for inhibiting the activity of 
GATA3, therefore limiting the onset of natural killer cell-like properties 
(Braunstein & Anderson, 2012).  Important to this discussion is that the ITNKs 
from mature T cells demonstrate compromised downstream TCR signaling (Li et 
al., 2010).  Chromatin-immunoprecipitation (ChIP) assays show Bcl11b promotes 
IL-2 gene expression following TCR activation, as well as increasing NF-κB 
activity (Cismasiu et al., 2006, 2009).  This research contradicts an earlier view of 
Bcl11b as a repressive transcription factor, and highlight a more complex 
mechanism behinds its activity.  Overall, there is strong support for Bcl11b’s 
critical role in transcriptional regulation of T cells, and this illustrates a potential in 
HIV transcriptional control. 
 Bcl11b is also referred to as CTIP2 (COUP-TF-interacting protein-2), 
because it was independently discovered to be associated with members of the 
chicken ovalbumin upstream promoter transcription factor (COUP-TF) (Avram et 
al., 2000).  COUP-TF family members typically mediate transcriptional repression 
through NCoR (Shibata, Nawaz, Tsai, O’Malley, & Tsai, 1997).  Bcl11b has also 
been shown to functionally associate with the nucleosome remodeling 
deacetylase (NuRD) complex with recruitment of HDAC1 and HDAC2 to the HIV 
promoter (Marban et al., 2007).  In the context of HIV latency within microglial 
cells, Bcl11b associates with lysine-specific demethylase 1 (LSD1) to promote 
heterochromatin formation and inhibit transcription (Le Douce et al., 2012).  
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These relevant associations highlight the significance of the current study in the 
context of HIV latency.  Bcl11b has a critical role in regulating transcription in 
mature T cells, and specifically HIV transcription, making it a potential target for 
future therapies against HIV infection. 
As discussed, there is a clear need for further elaboration on the pathways 
for recruitment of host-cell factors to the HIV LTR, and specifically, to identify T-
cell specific programs such as those mediated by Bcl11b that negatively regulate 
HIV transcription. The current study aims to identify a defined role for Bcl11b in 
the context of HIV latency. 
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SPECIFIC AIMS 
 
The establishment and maintenance of HIV-1 latency provides a critical 
barrier to complete eradication of the virus from an infected individual.  A major 
contribution to HIV-1 latency is the cessation of viral transcription. Previous 
research from our lab has shown that Bcl11b interacts with NELF-B as part of a 
paused RNA polymerase II complex.  Our present study aims to test the 
hypothesis that Bcl11b represses HIV transcription and is recruited to the HIV-1 
LTR through a paused RNA polymerase II complex, contributing to the 
establishment and maintenance of latency.  To test the hypothesis, we will: 
a) Determine whether Bcl11b inhibits HIV-1 transcription. 
b) Examine if there is a synergistic interaction between Bcl11b and NELF-B 
in repressing HIV-1 transcription. 
c) Explore the direct interaction between Bcl11b and NELF-B. 
 
These studies will define a role, if any, of Bcl11b in the maintenance of 
HIV latency.  We hope that this research will broaden the understanding of the 
transcription factors involved in RNA polymerase II pausing and limiting HIV-1 
transcription.  Furthermore, these studies are expected to identify potential T-cell 
specific targets that control HIV-1 transcription and latency. 
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METHODS 	  
Cell Culture: 
 HEK 293T cells (ATCC) are a stable line of human embryonic kidney cells.  
The HEK 293T cells (ATCC) were cultured in complete Dulbecco’s Modified 
Eagle Serum (cDMEM), supplemented with 10% fetal bovine serum, 100 units/ml 
penicillin, 100 µg/ml streptomycin, and 0.2 M L-glutamine.  BD Falcon 100mm x 
20mm culture dishes were used for cell culture.  The Jurkat E6.1 cell line (ATCC) 
is a stable T-lymphocyte developed by Schneider et al., 1977. Jurkat E6.1 cells 
were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 
100 units/ml penicillin, 100 µg/ml streptomycin, and 0.2 M L-glutamine. All cells 
were incubated at 37°C and 5% CO2.  
 
Cell Transfection: 
 Initial transfection experiments were conducted in HEK 293T cells.  First, 
cells were plated in 6-well plates at a density of 5.0x105 cells in cDMEM and 
incubated overnight at 37oC and 5% CO2.  Cells were then transfected using 
calcium phosphate with 2 µg of pNL4-3-Luc(+) Env(-) Nef(-) (HIV-LUC) and 4 µg 
of the targeted DNA per condition.  The four conditions for these transfections 
were as follows: 4 µg pcDNA3-Vec; 2 µg pcDNA3-Vec and 2 µg Bcl11b-HA; 2 µg 
pcDNA3-Vec and 2 µg pcDNA3-FLAG-NELF-B; and 2 µg Bcl11b-HA and 2 µg 
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pcDNA3-FLAG-NELF-B (refer to Table 1).  Cells were transfected for 2 hours, at 
which time the transfection media was changed for fresh cDMEM and incubated 
for 48 hours at 37o and 5% CO2.  HIV-LUC transcription was measured by 
luciferase activity (luciferase kit, Promega, Madison, WI), and p24 enzyme-linked 
immunosorbent assay (ELISA) measured by PerkinElmer Life Sciences ELISA 
kit. 
 
Table 1. Conditions for 293T Co-transfection: 
Plasmid Control (µg) Bcl11b (µg) NELF-B (µg) Bcl11b + 
NELF-B (µg) 
HIV-LUC 
 
2 2 2 2 
pcDNA3-Vec 
 
4  2  2 0 
Bcl11b-HA 
 
0 2 0 2 
FLAG-NELF-B 
 
0 0 2 2 
 
  
A subsequent transfection of HEK 293T cells was conducted using 
shBcl11b plasmids.  The protocol remained the same as previous transfections.  
The experimental plasmids used were 2 µg of an shBcl11b plasmid (control, or 
A-D), and 2 µg of Bcl11b-HA.  Whole cell lysates from the transfection were 
analyzed by Western blot analysis. 
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Establishment of Stable Cell Lines: 
  Jurkat E6.1 cells were used for a Bcl11b knockdown line.  HEK 293T cells 
were transfected with VSV-G and a puromycin-resistant shBcl11b (Origene) 
vector (control, or A-D) for 2 hours.  After 48 hours incubation at 37o and 5% 
CO2, media supernatants were collected, filtered with a 0.2 mm filter, and used to 
spinoculate Jurkat E6.1 cells with polybreen (10 µg/ml).  Cells were suspended in 
cRPMI and allowed to recover overnight.  Over 4 weeks stable lines were 
established using cRPMI with 1.0 µM puromycin.  Whole cell lysates were 
collected, and analyzed by western blot analysis and immunoprecipitation. 
 To establish a stable cell line with overexpression of Bcl11b, Jurkat cells 
were electroporated with the desired plasmids (pcDNA3-Vec or HA-Bcl11b).  
Electroporation was done with a BTX electroporator with a cuvet size of 4 mm at 
240V, and a low voltage 65 msec gap.  Cells were recovered overnight in cRPMI.  
Positive selection carried out using G418 (Geneticin) over 4-week period to 
generate a stable population.  Whole cell lysates were collected, and analyzed by 
western blot analysis and immunoprecipitation. 
 
Antibodies: 
 For Western blot analysis, immunoprecipitation, and chromatin 
immunoprecipitation, the following antibodies were used: anti-FLAG and anti-β-
actin from Sigma-Aldrich, anti-NELF-B (COBRA) (PhosphoSolutions), anti-HA 
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(Cell Signaling Technologies), anti-Bcl11b (Bethyl Laboratories), anti-Mouse-
HRP and anti-Rabbit-HRP (Upstate Biotechnology), anti-Mouse-TrueBlot-HRP 
and anti-Rabbit-TrueBlot (Rockland Immunochemicals), anti-Rabbit-Ig (Millipore),  
anti-NCoR1 (Thermo Scientific), anti-Pol II, and anti-p50.  The dilutions used 
during western blot analyses and immunoprecipitation analyses are listed below 
in Table 2. 
 
Table 2: Antibodies and the associated dilutions used for Western blot or 
immunoprecipitation detection.  All antibodies were dissolved in 5% non-fat 
milk. 
 
Primary 
Antibody 
Dilution Secondary Antibody Dilution 
Anti-FLAG 1:15,000 Anti-Mouse-HRP 
or 
Anti-Mouse IgG-TrueBlot 
1:30,000 
 
1:5,000 
Anti-NELF-B 1:5,000 Anti-Rabbit IgG-HRP 
or 
Anti-Rabbit IgG-TrueBlot 
1:15,000 
 
1:5,000 
Anti-HA 1:20,000 Anti-Mouse-HRP 
or 
Anti-Mouse IgG-TrueBlot 
1:40,000 
 
1:5,000 
Anti-Bcl11b 1:1,000 Anti-Rabbit IgG-HRP 
or 
Anti-Rabbit IgG-TrueBlot 
1:15,000 
 
1:5,000 
Anti-β-actin 1:5,000 Anti-Mouse-HRP 
or 
Anti-Mouse IgG-TrueBlot 
1:20,00 
 
1:5,000 
Anti-NCoR1 1:5,000 Anti-Rabbit-HRP 1:20,000 
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Western Blot Analysis: 
 Whole cell extracts from transfections were collected by resuspending 
cells in lysis buffer (10 mM Tris-Cl (pH 7.4), 150 mM NaCl, 1.0 mM EDTA (pH 
8.0), 2.0 mM sodium vanadate, 10 mM sodium fluoride, 10 mM sodium 
pyrophosphate, 1% Triton X 100, 1.0 mM phenylmethylsulfonyl fluoride, and 
protease inhibitor mixture III (Calbiochem).  The suspensions were spun down for 
5 minutes at 4oC at 13,000 rpm, and the supernatants collected.  Extracts were 
suspended in SDS-PAGE loading buffer and resolved on 8% SDS-PAGE.  The 
proteins were transferred to a PVDF blotting membrane (Millipore) via 
electroblotting.  Membranes were then blocked with a blocking buffer of 5% non-
fat milk in PBST for 1 hour.  The membrane was incubated in the desired primary 
antibody with the dilution mentioned in Table 2 in blocking buffer for 1 hour, 
followed by a final incubation in the necessary secondary antibody.  The 
membrane is then incubated in GE Healthcare’s ECL Prime Western Blotting 
Detection System for 5 minutes.  Film was exposed on membrane and 
developed with a Kodak X-OMAT. 
 
Immunoprecipitation and Immunoblots: 
 For immunoprecipitation, whole cell extracts were prepared by the same 
method for Western blot analysis.  After collecting the supernatant from the initial 
lysis, the samples were pre-cleared with protein A/G beads (Santa Cruz 
Biotechnology, catalog no. sc-2003) for 1 hour at 4oC.  Supernatants were 
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incubated with anti-NELF-B, ant-Bcl11b, or anti-Rabbit IgG for 1 hour at 4oC.  
Protein A/G beads were added to each condition and incubated for 1 hour at 4oC.  
Beads were collected, washed three times with fresh lysis buffer, and suspended 
in 2x SDS-PAGE loading buffer.  Samples were heated at 100oC for 5 mins and 
then resolved on 8% SDS-PAGE.  The proteins were transferred to a PVDF 
blotting membrane (Millipore) via electroblotting.  Membranes were then blocked 
with 5% non-fat milk and incubated in the appropriate antibodies for protein 
detection. 
 
Quantitative Real-Time PCR: 
 RNA was collected from cell extracts by suspending cells in TRIzol, and 
cDNA was formed using reverse transcriptase and random primer sets 
(Invitrogen).  1 ng of cDNA was used for quantitative real-time PCR reactions 
with SYBR Green reagent (Qiagen).  Elongated HIV transcripts (+5396 to +5531 
base pairs (bp)) were amplified using 5′-GACTAGAGCCCTGGAAGCA-3′ and 5′-
GCTTCTTCCTGCCATAGGAG-3′.  NELF-B mRNA was amplified using 5’-
GCGAGGTGGGGCTGTACTACG-3’ and 5’-GGCGGTGAGGAAGAAGCCATCG-
3’.  Bcl11b mRNA was amplified using 5’-GGGCGATGCCAGAATAGAT-3’ and 
5’-GGTAGCCTCCACATGGTCAG-3’.  For endogenous controls, β-actin mRNA 
was amplified using Quantitect primer assay (Qiagen).  PCR was carried out for 
40 cycles, and relative expression was calculated using the ΔΔCt method (Livak 
& Schmittgen, 2001).  Targeted amplification of transcripts was normalized to the 
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endogenous β-actin amplification of each condition.  Amplified products were 
compared to amplification in pcDNA3-Vec control condition, or shBcl11b-Control, 
and calculated as fold changes. 
 
Chromatin Immunoprecipitation: 	   Chromatin immunoprecipitation (ChIP) assay was carried out using the 
protocol described in Zhang et al., 2007.  For this study, 4.0x107 HEK 293T cells 
expressing pcDNA3-Vec, Bcl11b-HA, or FLAG-NELF-B were used.  The cells 
were cross-linked by using an 11% formaldeyde solution (prepared from 37% 
formaldehyde, 10% methanol stock solution (Merck)) in 0.1 M NaCl, 1 mM EDTA, 
0.5 mM EGTA, 50 mM Tris-HCl (pH 8), diluting to the final concentration of 1%, 
and incubated at room temperature for 10 min.  Cells were quenched by adding 2 
M glycine to a concentration of 240 mM, and then collected by centrifugation at 
700 x g for 10 min.  Cells were washed with phosphate-buffered saline (PBS) 
and resuspended in sonication buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5 
mM EGTA, 0.5 mM PMSF, 1%SDS) to be sonicated on ice for 30 cycles of 10 s 
on and 30 s off.  Samples were then suspended in 10 mM Tris-HCl (pH 8.0), 1 
mM EDTA, 0.5 mM EGTA, 0.5 mM PMSF, 0.1% SDS, and 1.1% Triton X-100, 
and incubated with 1 µg of targeted antibodies overnight at 4oC.  Protein A/G 
beads (Santa Cruz Biotechnology, catalog no. sc-2003) were added, incubated 
for an additional 2 hours, and collected by centrifugation at 3000 rpm for 5 min.  
Beads were washed three times with a low-salt buffer (0.1% SDS, 1% Triton X-
	  	  	   26 
100, 2 mM EDTA, 20 mM Tris-HCl (pH 8.0), and 150 mM NaCl), two times with a 
high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl (pH 
0.1), and 500 mM NaCl), and two times with a LiCl buffer (0.25 M LiCl, 1% 
Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, and 10 
mM  Tris-HCl, 1 mM EDTA).  Samples were eluted with an elution buffer (1% 
SDS and 0.1 M NaHCO3), reverse-cross-linked at 65 oC for 15 h, and treated with 
proteinase K at 45oC for 1 h.  DNA extracted by two phenol/chloroform 
extractions and precipitated in ethanol at -80oC for 1 h.  Analysis performed by 
real-time-PCR using SYBR green reagents, and the primers 5’-
GAGCCCTCAGATCCTGCATA-3’ and 5’-AGGCTTAAGCAGTGGGTTCC-3’ to 
amplify -45 to +72 bp of the HIV LTR, the primers 5’-
CTGGGAGCTCTCTGGCTAACTA-3’ and 5’-
TTACCAGAGTCACACAACAGACG-3’ to amplify +30 to +134 bp of the HIV LTR, 
and the primers 5’-ACAGTACTGGATGTGGGTGATG-3’ and 5’-
AATCCCTGGTGTCTCATTGTTT-3’ to amplify +2415 to +2522 bp of the HIV 
LTR. 	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RESULTS 	  	  	   The repressive function of Bcl11b was investigated in HEK 293T cells 
using an overexpression strategy.  Cells were co-transfected with the HIV-LUC 
provirus, and Bcl11b-HA or FLAG-NELF-B, or both.  Protein expression was 
confirmed by Western blot analysis, and HIV-LUC transcription was measured 
with a luciferase assay.  When co-transfected with Bcl11b or NELF-B, HIV 
transcription was reduced by approximately 43% and 53%, respectively, 
compared to the pcDNA3-Vec control (see Figure 5.A). When both factors were 
transfected together, HIV transcription was reduced by the greatest amount, 
approximately 76% (P-value = 0.0280).  Co-transfection of both factors had a 
significant decrease in HIV-LUC transcription when compared to NELF-B alone 
(P-value = 0.0347).  
 Analysis by p24 ELISA (Figure 5.B) depicts a similar trend as the 
luciferase activity.  The p24 protein is a viral capsid protein targeted for detection 
of HIV release from cells.  In all three of the experimental conditions, p24 
expression was significantly reduced.  Co-transfection with Bcl11b showed over 
50% reduction in p24 production, compared to pcDNA3-Vec control (P-value = 
0.0468).  NELF-B expression reduced p24 expression by nearly 80% (P-value = 
0.00770).  Co-transfection of both experimental plasmids showed the greatest 
reduction in p24 expression at nearly 85% (P-value = 0.0170).  Statistical 
comparison between the experimental conditions (Bcl11b or NELF-B vs. Bcl11b 
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+ NELF-B) revealed a significant difference between Bcl11b and the co-
transfection of both factors (P-value = 0.0187).  
 
 
 
Figure 5: 293T HIV-LUC Transfection with Overexpression of Bcl11b and/or NELF-
B.  (A) HEK293T cells were transfected with HIV-LUC, and either Bcl11b-HA or FLAG-
NELF-B, or both.  Relative light units were measured as an indicator of HIV-LUC 
transcription. (B) p24 ELISA measurements of cells transfected with HIV-LUC and 
indicated transcription factors.  
 
 
A.	  
B.	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Figure 5: 293T HIV-LUC Transfection with Overexpression of Bcl11b and/or NELF-
B.  continued (C) Western blot analysis from the transfected cells.  Conditions labeled 
with titles above the lanes, and probed with antibodies shown for the different rows. 
 
 
 
 
 Based on the Western blot analysis (Figure 5.C), the expression of Bcl11b 
when co-transfected with NELF-B appeared markedly decreased.  qPCR was 
performed in order to compare transcription of the experimental plasmids to the 
protein expression seen from the western blots.  As seen in Figure 6, the qPCR 
was clearly flawed, most likely in the collection of the RNA from the transfection 
samples, or the preparation of the cDNA.  Measured transcription levels of HIV 
elongated transcripts and Bcl11b do not follow the trends shown in the luciferase 
assay and p24 ELISA.  However, transcription levels of NELF-B do show a 
significant increase in the two conditions transfected with FLAG-NELF-B. 
C.	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Figure 6: qPCR Analysis of 293T Overexpression.  Depicted is the relative 
increase/decrease in transcription of the targeted transcript. (A) HIV elongated 
transcripts shown for cells transfected with HIV-LUC and the indicated transcription 
factors.  (B) Measurement of Bcl11b transcription between transfection conditions.  (C) 
Measurement of NELF-B transcription between transfection conditions.  
A. 
B. 
C. 
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 In order to investigate an interaction between Bcl11b and NELF, 
immunoprecipitations (IP) were performed.  Using whole cell lysates co-
expressing Bcl11b-HA and FLAG-NELF-B, the IP was executed using an anti-
Bcl11b antibody followed by Western blot analysis.  This strategy successfully 
displayed enrichment of the targeted protein (Bcl11b); however, NELF-B was not 
found to be associated with Bcl11b in this experiment.  Figure 7.A shows this IP 
probed with anti-Bcl11b antibody, confirming successful pull-down of Bcl11b in 
the 293T sample.  Figure 7.B shows the same IP, now probed with anti-NELF-B 
antibody.  NELF-B does not appear in the anti-Bcl11b IP lane, but is shown in the 
10% input and flow through lanes.   
 
 
Figure 7: 293T anti-Bcl11b Immunoprecipitation.  (A) Bcl11b was pulled down 
using an anti-Bcl11b antibody; detection with anti-Bcl11b (B) Blot is probed with 
anti-NELF-B detection antibody. 
 
  
 
A. B. 
	  	  	   32 
To explore the potential physical interaction of Bcl11b and NELF, we 
expanded our search into the T lymphocyte derived cell line: Jurkat E6.1 cells.  
As opposed to HEK293T cells, Jurkat E6.1 cells endogenously express Bcl11b, 
so no overexpression strategy was used prior to collecting whole cell lysates.  
The same IP strategy was performed as in HEK293T cells for the Jurkat E6.1 
whole cell lysates (Figure 8).  In addition to the anti-Bcl11b IP, an anti-NELF-B IP 
was also performed.  Consistent with the previous IP in HEK293T cells, the anti-
Bcl11b IP did not show an endogenous complex with NELF-B.  For the anti-
Bcl11b IP, the result was the same, with no NELF-B and Bcl11b complex 
detected.  Each protein appeared in a 10% input sample, and showed successful 
enrichment in their experimental IP lanes. 
 
Figure 8: Immunoprecipitations in Jurkat E6.1 Cells.  Immunoprecipitations in 
Jurkat E6.1 cells performed using anti-Bcl11b or anti-NELF-B in order to pull 
down possible protein complexes.  Western blot probed with anti-Bcl11b or anti-
NELF-B detection antibody (labeled on the left).  Conditions are labeled above 
the respective lanes, and protein expression labeled on the right of the blot.   
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After investigating the impact of overexpressing Bcl11b overexpression, 
we focused on the effect of knocking down Bcl11b expression.  As a transcription 
factor potentially linked to the maintenance of HIV latency, but also critical in the 
maintenance of T-cell activation; researching the effects of domonishing Bcl11b 
are important for understanding its role as a potential therapeutic target.  To 
determine which shRNAs could reduce Bcl11b most efficiently, knockdown 
studies were initially performed in HEK293T cells followed by Western blot 
analysis.  The study was accomplished by transfecting an shBcl11b plasmid 
(control, or A-D) with a Bcl11b-HA plasmid.  Western blot analysis was 
performed on the whole cell lysates to view the varying expression of Bcl11b 
between the conditions (Figure 9).  As shown, the plasmids shBcl11b-A, 
shBcl11b-B, and shBcl11-D appeared to limit the expression of Bcl11b compared 
to the shBcl11b-Control.  Using this knowledge, these three plasmids were 
chosen to be packaged with a VSV-G pseudotyped virus and spinoculated into 
Jurkat E6.1 cells.   
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Figure 9: Co-transfection of Bcl11b and shBcl11b plasmids in HEK293T 
cells.  HEK293T cells were transfected with Bcl11b-HA and varying shBcl11b 
plasmids.  Whole cell lysates collected after 48 hours, and Western blot analysis 
is shown.  Condition of the transfection is labeled above the respective lane, with 
the detection antibodies marked by the rows. 
 
 
 We then used shRNA to limit Bcl11b expression in T cells, and for these 
experiments we used Jurkat E6.1 cells.  In Figure 10, Western blot analysis, 
Bcl11b was successfully reduced in the Jurkat E6.1 cells.  Similar to the 
HEK293T co-transfection, the shBcl11b-D plasmid was able to limit Bcl11b 
expression to the greatest extent.  Knowledge of this knockdown efficiency will 
allow us to establish a stable Bcl11b knockdown line for future HIV infection 
studies in Jurkat E6.1 cells and other T-cell lines. 
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Figure 10: Bcl11b knockdown in Jurkat E6.1 cells.  Using a VSV-G 
pseudotyped virus containing three different shBcl11b plasmids (A, B, or D), 
Bcl11b expression was inhibited in Jurkat E6.1 cells.  Western blot analysis of 
whole cell lysates is shown with the indicated conditions above the lanes, and 
probed with antibodies indicated in the rows. 
 
 
 To investigate the interaction of our experimental factors with particular 
regions of the HIV provirus, chromatin immunoprecipitation (ChIP) was 
performed on HEK293T cells.  An HIV LTR -45 to +72 primer set was used in 
order to see association of the transcription factors with the transcriptional start 
site.  Figure 11 below depicts the results of the ChIP.  The most striking finding of 
the ChIP is the relative increase in RNA Pol II found at the HIV transcriptional 
start site, measured by anti-Pol II antibody pull down in the Bcl11b-HA condition.  
This increase over the other conditions could suggest a promoter-proximal 
paused RNA Pol II complex associated with overexpression of Bcl11b.  Seeing 
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no significant difference in measured transcripts pulled down by anti-Bcl11b 
when overexpressing Bcl11b disputes the previously seen binding to the HIV-1 
LTR (Cismasiu et al., 2008).  However, Bcl11b could be binding upstream of the 
region for the primer set in this study, and there could be cell line-specific 
challenges when comparing our studies in HEK293T cells to the more relevant T 
lymphocyte derived cell lines. 
 
 
 
Figure 11: ChIP of HEK293T cells transfected with Bcl11b-HA or FLAG-
NELF-B.  ChIP was performed using the targeted antibodies listed along the 
horizontal axis.  The primer set used was -45 bp to +72 bp of the HIV-1 LTR.   
The vertical axis indicates the relative amount of measured transcript.  
	  	  	   37 
DISCUSSION 
 
The AIDS pandemic continues to take the lives of millions of individuals 
every year; however, the increasing efficiency and availability of ART is 
decreasing the annual death rate.  Current therapeutic strategies have changed 
a fatal diagnosis into a manageable, chronic disease.  Unfortunately, the battle is 
not won, as ART merely decreases viral loads to clinically undetectable levels, 
leaving patients dependent on costly and highly frequent medications.  
Furthermore, upon cessation of these treatments, viral load rebounds and AIDS 
symptoms return.  The advent of ART was a huge step in the global fight against 
HIV infection, but it is now clear that targeting the latent cell reservoirs will be 
necessary to find a cure. 
A significant hurdle to activating transcription of HIV in latent reservoirs is 
overcoming promoter-proximal pausing of the RNA polymerase II complex.  This 
form of transcriptional silencing is maintained by either a presence or absence of 
several host cell nuclear transcription factors.  Of particular interest are Bcl11b 
and NELF, which have already been associated with transcriptional repression.  
Bcl11b, primarily known as a T-cell commitment factor that limits the expression 
of a variety of genes to maintain a T-cell identity during development, is known to 
associate with other HIV repressive factors such as NuRD and histone 
remodeling enzymes.  Preliminary research from our lab has indicated an 
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interaction between Bcl11b and NELF, leading to this current study on the role of 
Bcl11b in HIV transcription. 
Initial transfections of HEK293T cells confirm the repressive activity of 
Bcl11b, as well as NELF-B. Together, Bcl11b and NELF-B significantly reduce 
HIV to an even greater extent (Figure 5), further suggesting a possible 
relationship in their mechanism of action at the HIV transcription start site.  
However, Western blot analysis shows lower levels of Bcl11b expression when 
expressed with NELF-B.  Since NELF-B is a general repressor of transcription, it 
is thought that it is inhibiting expression of Bcl11b transcription which prompted 
qPCR analysis of the mRNA expression.  Unfortunately, our results of this 
analysis (Figure 6) are flawed and do not uncover the problem.   
We suggest that there is a connection between the repressive 
mechanisms of Bcl11b and NELF.  However, our studies of the possible 
interaction of Bcl11b and NELF do not reveal a direct physical interaction.  
Following discovery of a successful immunoprecipitation strategy for these 
particular transcription factors, our results indicate that there is no direct 
interaction between the factors.  This finding suggests that if these factors share 
a common pathway for HIV repression, there may be a yet to be identified 
intermediate factor coordinating the interaction.  We suggest that this factor could 
be NCoR1 or HDAC3, which would be consistent  with our previous mass 
spectrophotometry data, as well as with the current literature.  Furthermore 
immunoprecipitations need to be performed in Jurkat cells overexpressing 
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Bcl11b to fully rule out a direct physical interaction with NELF. Stable Bcl11b 
overexpression and knockdown lines were successfully established in Jurkat 
cells.  Future studies will examine the outcomes of HIV infection in these stable 
cells lines. 
Inhibition of HIV transcription is associated with a nucleosome positioned 
at the transcriptional start site.  Reversal of the repression occurs with chromatin 
modifications by histone deacetylases and histone methyl transferases.  Bcl11b 
has been shown to interact with both nucleosome remodeling complexes (NuRD) 
and histone remodeling factors, and we suggest that recruitment of these factors 
is the mechanism behind the repression of HIV transcription seen in our studies.  
Further experiments are required to highlight the pathway of recruitment of these 
factors by Bcl11b in CD4+ T cells. 
Previous studies performed by Cismasiu et al., 2008 suggest that Bcl11b 
binds directly to the HIV-1 LTR and is involved in recruitment of the NuRD 
complex, and it is through this promoter proximal binding and nucleosome 
remodeling that transcription is blocked.  In order to further investigate this 
mechanism, future experiments should include a ChIP targeting Bcl11b and 
NuRD, to measure HIV-1 transcripts further upstream from the transcriptional 
start site.  Also, as previously mentioned, Bcl11b is involved in the NF-κB 
signaling pathway, an important mechanism behind T-cell activation.  Future 
experiments will include HIV-LUC constructs that have a mutated NF-κB binding 
site in order to explore the connection in signaling pathways. This would expand 
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our current understanding of Bcl11b’s mechanism of repression.  Furthermore, it 
is important for the context of HIV-1 latency to expand our current experiments 
into establish latent cell lines, such as ACH2 cells.  Comparing overexpression, 
or repression, of Bcl11b expression in a latent cell line to primary CD4+ T cells 
will elaborate upon Bcl11b’s impact to maintaining cellular latency. 
Overall, these studies have confirmed Bcl11b having a repressive role in 
HIV-1 transcription.  Early transfection experiments continue to indicate a 
synergistic role of Bcl11b and NELF-B in inhibiting HIV-1 transcription, but their 
physical interaction remains veiled behind a possible intermediate factor that we 
have yet to associate with this complex.  Further studies including other 
associated transcription factors, such as NCoR1 and NuRD, need to be 
performed to help further illustrate the mechanisms behind promoter-proximal 
RNA polymerase II pausing in HIV-1 latent cell populations.  As a critical T-cell 
commitment factor, Bcl11b may also be a significant factor in maintaining latent 
HIV-1 provirus reservoirs.  A greater understanding of the intricate mechanisms 
behind HIV-1 transcriptional silencing, and premature termination are critical to 
uncover future therapeutic strategies targeted at purging HIV-1 latent cell 
reservoirs. 	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